Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Tyler Maclay, Melinda Day, Kevin Mills
Title CYT01B, a novel RAD51 inhibitor, acts synergistically with PARP inhibitors
Journal AACR Annual Meeting 2019 Online Proceedings
Vol
Issue
Date
URL https://www.abstractsonline.com/pp8/#!/6812/presentation/2996
Abstract Text AACR Annual Meeting 2019, Abstract 363

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable CYT01B + Veliparib Preclinical - Cell culture Actionable In a preclinical study, CYT01B and Veliparib (ABT-888) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). detail...
Unknown unknown Advanced Solid Tumor not applicable CYT01B + Olaparib Preclinical - Cell culture Actionable In a preclinical study, CYT01B and Lynparza (olaparib) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). detail...
Unknown unknown Advanced Solid Tumor not applicable CYT01B + Niraparib Preclinical - Cell culture Actionable In a preclinical study, CYT01B and Zejula (niraparib) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). detail...
Unknown unknown Advanced Solid Tumor not applicable CYT01B + Talazoparib Preclinical - Cell culture Actionable In a preclinical study, CYT01B and Talzenna (talazoparib) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). detail...
Unknown unknown Advanced Solid Tumor not applicable CYT01B + Rucaparib Preclinical - Cell culture Actionable In a preclinical study, CYT01B and Rubraca (rucaparib) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). detail...